"Women have been an afterthought in the longevity space": Wisp CEO announces peptide partnership with Vesalius
Wisp announces strategic collaboration with Vesalius Longevity Labs
U.S women’s telehealth provider Wisp has announced plans to develop a new range of peptide-based therapeutics designed specifically for women.
Through a strategic partnership with Vesalius Longevity Labs, the move marks Wisp’s entry into the fast-growing longevity market, which has been widely viewed as dominated by products and research focused on men.
Vesalius, the company behind the peptide brand Peptual, is preparing to go public as one of the first longevity-focused companies on the market. Together, the two firms plan to design peptide therapies aimed at improving women’s quality of life and extending healthy lifespan.
Peptides for women’s health
The global peptide therapeutics market - currently valued at $43.1 billion and projected to reach $106 billion by 2033 - has seen rapid expansion in recent years. Peptides, short chains of amino acids that act as messengers in the body, help regulate metabolism, hormone balance, and tissue repair. While they have been long used in clinical medicine, they’ve become increasingly popular in wellness and performance circles, particularly among men. Wisp and Vesalius want to change that - redirecting the science toward women’s health with targeted treatments for fertility, menopause, and aging.
“Women make up half the population, yet they’ve been treated like an afterthought in the longevity space,” said Monica Cepak, CEO of Wisp.
“Our mission is to close that gap by making advanced therapeutics both accessible and affordable for women at every stage of life. By partnering with Vesalius, we’re introducing peptides into women’s healthcare and expanding access to a powerful tool that can transform how women age.”
The partnership will draw on Vesalius’ existing Peptual line of injectables, patches, nasal sprays, oral, and topical formulations - most of which are U.S.-sourced. The companies plan to launch a comprehensive product portfolio by early 2026, with offerings designed to meet women’s specific biological needs throughout life.
In addition to product development, Wisp and Vesalius will jointly explore the use of artificial intelligence in longevity and personalized medicine. The companies said they will evaluate AI platforms for potential integration, focusing on tools that can support clinical decision-making, patient engagement, and tailored care plans.
“Our product innovation team and globally recognized Scientific Advisory Board are committed to working closely with Wisp to accelerate access to safe, effective solutions,” said Kevin Rabbitt, CEO of Vesalius Longevity Labs.
“By combining Vesalius’ expertise in longevity science with Wisp’s leadership in women’s healthcare, we’re ushering in a new era that will meaningfully extend women’s lifespan.”
For Wisp, the move builds on a series of recent expansions beyond telehealth consultations. This week, the company also launched two supplements - Wisp Thrive Creatine Tablets and Wisp Revive Collagen Tablets - marking its first step into the longevity category. The partnership with Vesalius represents the next phase of that strategy: positioning Wisp as a long-term player in preventive and age-optimization care.
The significance of the deal lies in its focus on women’s longevity - a field where research and product development have historically lagged behind men’s health initiatives. By combining Wisp’s digital care infrastructure with Vesalius’ biotech capabilities, the companies are betting that demand for female-focused anti-aging and wellness therapies will continue to rise, driven by shifting demographics and greater public attention to gender gaps in health innovation.